about
Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literatureUnderstanding patients' perspective in the use of generic antiepileptic drugs: compelling lessons for physicians to improve physician/patient communication.Impact of generic substitution decision support on electronic prescribing behaviorGeneric products of antiepileptic drugs (AEDs): is it an issue?Exposure to CYP3A4-inducing and CYP3A4-non-inducing antiepileptic agents and the risk of fractures.Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.Substitution of anticonvulsant drugs.Requirements for generic anti-epileptic medicines: a regulatory perspective.The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.Generic substitution of antiepileptic drugs.Requirements for generic antiepileptic medicines: a clinical perspective.Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study.Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany--a nationwide population-based study in children and adults.Inhibitory role of Acorus calamus in ferric chloride-induced epileptogenesis in rat.Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).Factors influencing the use of the "not for generic substitution" mention for prescriptions in primary care: a survey with general practitioners
P2860
Q26749431-DDE6D6D7-1737-4C97-B029-21CE02C2F573Q33418937-75042DD8-0BDB-444B-A1E4-D8245254E906Q34399756-6D5A8D4D-B5C2-463F-84C0-F0294AC32458Q34582885-58B0B351-F4DA-4449-A3E4-05DAAB3D94E6Q35120734-9E3D1C47-DF1F-4562-A5D6-361E980ECA56Q36916999-FDFECDD6-D99B-40BF-BF60-0B8295AF7D7CQ37240298-CADC798E-6666-4722-BA98-2A8BE2D6609CQ37428755-8E915AD8-8E81-4048-BE64-22F5A0CF5CC0Q37575533-93B27DA5-DF18-4C8F-85D6-074F14A2027EQ37810997-FA32884F-D2BC-4A08-BC11-EBCE4FF1F4AAQ37888545-97D4480F-DB7C-4F7F-80B7-35CF416401A0Q40512938-221E0269-39E2-4E37-BE2F-95728A61BED8Q43843541-36E0CEC1-B4F2-41DA-AB16-D0E1B3BECCC3Q46674715-6CB74D63-5EBC-46E8-9545-FFC215381868Q47847824-B2E50C94-9015-4BA3-B94F-1FCD389F13DCQ59136179-CBBEEA92-DFB5-4031-8416-6F53873A6FFC
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Antiepileptic drugs: generic versus branded treatments.
@ast
Antiepileptic drugs: generic versus branded treatments.
@en
type
label
Antiepileptic drugs: generic versus branded treatments.
@ast
Antiepileptic drugs: generic versus branded treatments.
@en
prefLabel
Antiepileptic drugs: generic versus branded treatments.
@ast
Antiepileptic drugs: generic versus branded treatments.
@en
P1433
P1476
Antiepileptic drugs: generic versus branded treatments.
@en
P2093
Dominic C Heaney
P304
P356
10.1016/S1474-4422(07)70105-9
P50
P577
2007-05-01T00:00:00Z